All peptides
CardiovascularResearch Phase

Urocortin 2

Intravenous
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

Urocortin 2 is a 38-amino acid peptide member of the corticotropin-releasing factor family with selective affinity for CRF receptor 2. It exerts cardiovascular effects including coronary and peripheral vasodilation, increased cardiac contractility, and protection against ischemia-reperfusion injury through receptor-mediated cyclic AMP signaling.

Mechanism of Action

The selective receptor profile distinguishes it from urocortin 1 and may offer advantages in minimizing stress-axis activation.

Research Summary & Key Findings

Preclinical studies in animal models have demonstrated that urocortin 2 improves cardiac output and reduces myocardial injury in heart failure and ischemia models. Limited early-phase human data exist, and the peptide remains in the research phase without published clinical efficacy trials for cardiovascular indications.

Clinical Status

Research Phase

Urocortin 2 is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Intravenous

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Cardiovascular

Start Your Consultation

Get an AI-proposed Urocortin 2 protocol reviewed by a physician in our network.

Start Your Consultation

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Urocortin 2.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.